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Abstract 
Lateral flow assays (LFA) are quick, simple and cheap assays to analyse a variety of samples at the point 
of care or in the field, making them one of the most widespread biosensors currently available. They have 
been successfully employed for the detection of a myriad of different targets (ranging from atoms up to 
whole cells) in all type of samples (including water, blood, foodstuff and environmental samples). Their 
operation relies on the capillary flow of the sample within a series of sequential pads with different 
functionalities aiming to generate a signal indicating the absence/presence (and, in some cases, the 
concentration) of the analyte of interest.  In order to have a user-friendly operation, their development 
requires the optimization of multiple, interconnected parameters that may overwhelm new developers. 
In this Tutorial we provide the readers with: 1) the basic knowledge to understand the principles governing 
an LFA and to take informed decisions during lateral flow strip design and fabrication, 2) a roadmap for 
optimal LFA development independent of the specific application, 3) a step by step example protocol for 
the assembly and operation of an LF strip for the detection of Human Immunoglobulin G and 4) an 
extensive troubleshooting section addressing the most frequent issues in designing, assembling and using 
LFAs.        
 
Introduction 
The simplicity and low cost of lateral flow assays (LFAs) have made them one of the most used point-of-
care (PoC) sensors1,2 in a variety of disciplines ranging from diagnostics3–6 to environmental7–9 and safety10–
14 analysis. Their success lies in their general design that has remained almost unchanged since their first 
use as pregnancy tests in 1970s.15 Although all LFAs simply rely on capillary forces to move the sample 
along a test strip to generate a measurable signal, their fabrication is far from being straightforward.16 In 
fact, in order to provide the end user with an easy-to-use device, developers must consider and evaluate 
multiple parameters, some even simultaneously, for optimal performance or market-readiness.17 For a 
new researcher or developer, this task may prove to be quite daunting. Fortunately, as it is a relatively 
´old´ and well-known technology, there are several resources online that discuss the general principles of 
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LFAs and even several guides are provided by both public and private entities.16,18–26 In addition, searching 
for “lateral flow assay” in Scopus generates over 7700 documents, with many of them describing the 
development of a new LFA for specific applications. Although the design and optimisation of tailored LFAs 
remains challenging, the target-specific nature of the assay makes it impossible to write a generalizable 
LFA protocol that works for all applications. Therefore, instead, in this Tutorial we have collected the 
knowledge to provide a general roadmap that can be used by developers to design, optimize, and 
fabricate an LFA for their specific application(s).  
 
General principles and components of lateral flow assays 
From a user perspective, operation of a well-designed LFA is strikingly simple: the assay is executed by 
adding the sample onto a single paper lateral flow strip (LF strip) and after a short incubation time, the 
positive or negative outcome of the test is revealed by the appearance of a line. Having a more detailed 
look (Fig. 1) at what happens to the sample after its application (assuming for a standard immune 
sandwich assay, although other formats are also possible see Box 2), we can see that it first encounters 
the sample pad, which assures that the characteristics of the sample match those required for optimal 
detection (pH, ionic strength, viscosity, purity and concentration of blocking agents). Next, the sample 
reaches the conjugate pad, which releases the labelled detection bioreceptor (e.g. an antibody, often –
conjugated to a nanoparticle for detection) upon wetting and allows for a first analyte-bioreceptor 
interaction. The sample then travels through the membrane (also called detection pad). In most LFAs 
there are at least two lines on the membrane: 1) the test line, where a capture bioreceptor binds the 
labelled analyte, generating a line that indicates the presence or absence of the analyte (most commonly 
visualised either by naked eye or by an optical reader); and 2) the control line, which assures the correct 
operation of the LFA (by selectively capture of the labelled bioreceptor). Finally, the sample reaches the 
absorbent pad, which provides enough bed volume for the complete flow of the sample.  
Overview of the Tutorial 
The design of the LF strip strongly depends on the type of sample and the target molecule to be detected. 
Therefore, we start this Tutorial by a discussion of the types of samples that can be analysed and the 
different challenges this raises. Next, we discuss how to select and characterise appropriate bioreceptors 
and how to choose the optimal type of nanoparticles for detection. Following this, we have a detailed look 
at the four main physical components of the LF strip: sample pad, conjugate pad, membrane and 
absorbent pad. We will examine in detail the effects that each component has on the LFA, and discuss the 
key characteristics developers should consider when choosing the most suitable materials and reagents 
for a specific target of interest. In addition, we provide a detailed step-by-step example procedure for the 




Figure 1: schematic of the main components and operation of a typical LFA. A) A LFA is made of four main 
parts: the sample pad, the conjugate pad, the membrane and the absorbent pad. They are mounted on a 
laminated card. The membrane contains the bioreceptors that form the test and control lines. The bottom 
part shows the operation of a LFA based on an immunosandwich recognition. B) The presence of the target 
in the sample produces the accumulation of nanoparticles on the test and control lines making the classical 
two red lines to appear. C) Instead the absence of the target makes the nanoparticles to accumulate just 
on the control line, giving a single coloured line output.       
 
Types of samples and target analytes 
As aforementioned, LFAs are used in a variety of applications with samples that present extremely 
different composition and characteristics (Table 1).27 For example, clinical samples can be whole blood,28,29 
plasma,30,31 serum,32–34 sweat,35,36 urine,37,38 stool,39,40 saliva,41,42 cerebrospinal fluid43,44 and nasal 
swabs,45,46 while food matrices could be juices,47,48 cereals,49,50 meat,51,52 vegetables,53 and environmental 
(mostly water and soil) samples.54–57 Although the sample pad provides a means to control the properties 
of the sample solution (see the following section), some complex matrixes may require pre-treatment 
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before an aliquot can be added into the LFA strip.58 For instance, the most obvious is the requirement for 
homogeneity of ground solid samples in specific buffers in order to allow for an even and steady flow 
through the LFA. For example when analysing solid food matrices the uneven distribution in their volume 
of toxic/pathogenic contaminants requires the use of large volume of samples that need to be 
homogenised.59 In the case of whole blood, its dark red colour and viscosity present challenges and various 
limitations for LFAs. Ideally, the separation of blood cells using external filtration units60 or by using an 
integrated special filtration membrane61,62 on the sample pad is recommended. However, the additional 
use of external filters may complicate the system for the end user and, moreover, sufficient purification 
is not always achieved. It is also possible to lyse the blood cells before adding the blood sample to the LF 
strip. However, this should be avoided (unless the target is within the cell) to prevent the release of other 
proteins and nucleic acids that can interfere with the specificity and sensitivity of the LFA.  
Besides making the sample suitable for running in an LFA, developers must also develop a simple yet 
standardized specimen collection protocol. To achieve reliable analytical results from different users, it is 
paramount that the sample collection procedures are consistent, in particular for LFAs requiring a 
quantitative reading.  For example, LFAs for urinary test often include a sterile cup to minimize 
contamination during specimen collection or porous plastic wicks to control the volume of sample and 
the flow speed. For stool samples, a small spatula is generally included for the uptake of a precise amount 
of sample and for its immersion in a provided homogenization solution. Nasal, saliva, skin and vaginal 
samples often provide surface contaminant controls and typically require the use of a cotton swab to 
capture molecules and particles from inner tissues and surfaces. The swab is then immersed into a 
provided solution to suspend and pre-treat the samples before its application to the lateral flow strip. In 
some special cases, like LFAs for whole blood samples, running and/or washing buffers are used. Their 
function is to guarantee the flow of the analyte along the LF strip even when the viscosity or the 
insufficient amount of sample would prevent it.  
TABLES 
Table 1: Considerations on pH, collection and treatment of different types of samples for their use in LFAs. 
Sample pH Collection Sample treatment Ref. 
Urine 4.5-7.2  Can be directly applied in 
some LFA. 
 Otherwise use of sterile 
containers. 
 Some patients might not 




 Sample pad buffer should 
aim at equalize the pH of 
different samples. 




Blood 7.35-7.45  Fingerprick.  
 Venous puncture. 
 
 If directly applied, a 
second running buffer is 
required. 
 Use of extra stacking pad 






 Requires the separation of 
cells from non-clotted 
blood, generally by 
centrifugation. 
 Special filters can 
separate plasma from 
blood without 
centrifugation, making the 
ideal approach for LFAs.224 
 A running/washing buffer 
is generally recommended 
upon sample addition.   
 It may require additional 
filtration prior application 





 Requires separation of the 
liquid portion from clotted 
blood, generally by 
centrifugation. 
 
 A running/washing buffer 
is generally recommended 
upon sample addition.   
 It may require additional 
filtration prior application 
to the LFA. 
32,33 
Sweat 3.5-8.5  The absorbent pad of an 
LFA is wiped across the 
skin. 
 An absorbent patch is 
sticked to the skin for 
several days (for example 
PharmCheck patches).  
 
 Use of a running buffer to 
either extract the sample 
from the patch or make it 
run through the sample 
pad.  
 Sample pad buffer should 










 Use of a running buffer to 
extract the sample from 
the swab.  
 The buffer may contain: 
mucins, surfactants and 
high salt concentrations 
for viscosity reduction. 
 
45,46 
Saliva 6.75-7.25  Collection in swabs or 
tubes. 
 Unstimulated: pooling 
saliva in the mouth and 
deposit into a specimen 
tube. It may involve food 
or drink contamination, 
higher viscosities, and air 
bubbles. 
 Stimulated: by chewing 
gum, by sucking on a 
lozenge or by swab-like 
collection devices. It may 
involve changes in pH, 
 Running/extraction buffer 
may contain: mucins, 
surfactants and high salt 
concentrations for 
viscosity reduction. 
 Centrifugation and 
application of the 
supernatant. 
 Special salt pad made of 
glass fibre with highly 
concentrated salt, placed 







 Time of collection should 
be registered for 




7.2-7.4  Lumbar puncture 
performed by a 
professional.  
 Collection in a sterile 
container. 
 Directly onto the strip and 
addition of running buffer. 
 Or addition of diluent in 
the container and then 
apply onto the strip. 
43,44 
Stool 6-7.2  Collection in a sterile 
container, followed by 
sampling with a dedicated 
spatula. 
 Homogenization of the 
sample contained in the 
spatula in 
running/extraction buffer. 
 Usually with tween20 for 
sample disruption. 
39,40 
Water 6.5-8.5  Can be directly applied. 
 Some low-concentrated 
analytes might require the 
concentration of the 
sample. 
 Dirty water may require 
special filtration.  
 Vacuum pumps and 
syringes might be used for 
sample pre-concentration. 
54–57 
Solid Food N/A  Uptake of small amount in 
sterile bags. 
 Very different matrices 





 Might require extra 
filtration capabilities. 




Liquid Food N/A  Can be directly applied. 
 Uptake of an aliquot in 
sterile containers 





In order for a bioreceptor (typically proteins, antibodies, DNA) to be effective in an LFA, it has to comply 
with three main characteristics: (1) it has to be stable, (2) it needs fast association kinetics and (3) should 
have a strong binding affinity for the target molecule. The stability of the bioreceptor means that it has to 
keep its structure and functionality in a variety of environments (different temperatures, humidity %, 
pressures)63 and, above all, it has to maintain its function after a cycle of drying and rewetting. In regards 
to this, fast target analyte binding kinetics are essential as there are practically no incubation steps on the 
LFA and the bioreceptors have to bind to the target within seconds. These two are important 
characteristics to be considered when selecting suitable antibodies as bioreceptors. In fact, most 
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commercial antibodies are characterized with techniques such as Enzyme Linked Immunosorbent Assay 
(ELISA) and western blot, which include long incubation steps, typically in the order of hours, and 
therefore, antibodies that work for ELISA and Western blot may not work for LFA. Finally, the binding 
between the bioreceptor and the target must be strong to obtain a stable signal. In practice, most of the 
labelled target will pass through the LFA strip and travel to the detection zone in matter of seconds. 
Meanwhile, the flow still continues for minutes and acts as an internal washing step. If the target-to-
bioreceptor binding is weak, the signal will decrease over time once the concentration of the labelled-
analyte in solution decreases.  
The choice of the proper bioreceptor is probably the most important step to achieving the required 
analytical sensitivity and specificity in an LFA. This is particularly challenging for the detection of protein 
targets given the large variety of possible bioreceptors (Table 2). Ideally, during the initial phases of an 
LFA development, several bioreceptors should be screened using a combinatorial approach where each 
bioreceptor is tested both in the test line and conjugated to the label nanoparticle. Depending on the 
resources and facilities available, the use of standard techniques (such as ELISA,64 Surface Plasmon 
Resonance (SPR),65 Biolayer interferometry (BLI)66 and Isothermal Titration Calorimetry (ITC)67)68 could 
speed up the screening of multiple bioreceptors. For example, ELISA can be used to evaluate dozens of 
antibody/antigen combinations to find those producing the most sensitive result in a relatively short 
amount of time. In this respect, the developer could minimize the duration of the incubation steps in 
order to eliminate the bioreceptors with slow binding kinetics. Moreover, SPR, BLI and ITC can provide 
useful information about the association and dissociation binding kinetics, although they are more 
expensive techniques than ELISAs. Indeed, these techniques can help to identify and shortlist the most 
promising bioreceptors, however, they must be finally tested in a real LFA, in order to choose those that 
will be used in the final assay since the kinetics can be different for binding in porous media.69 
 
Capture bioreceptors vs. detection bioreceptors.In order to avoid confusion, in this manuscript we will 
refer to the bioreceptors conjugated to the nanoparticles as “detection bioreceptors”, to the bioreceptors 
on the membrane as “capture bioreceptors”, which are further divided into “test line capture 
bioreceptors” and “control line capture bioreceptors”.  
Although it is important to test different combinations of detection and capture bioreceptors (ideally 
previously short-listed using standard techniques), from a theoretical perspective the latter should have 
a faster binding kinetic. The reason for this is that the interaction of capture bioreceptors with the analyte 
is limited to the instants during which the flow passes on the test line area, while the detection 
bioreceptors have slightly more time to bind to the analyte during the flow from the conjugate pad to the 
test line. Another aspect to consider for the development of a sandwich assay is that the detection 
bioreceptor should not interfere with the binding of the test line capture bioreceptor to the target. For 
example, during the testing of a sandwich assay using a monoclonal antibody and a polyclonal antibody, 
the monoclonal antibody should be the detection bioreceptor (it binds to just one epitope of the analyte) 
while the polyclonal antibody should be the test line capture bioreceptor (the binding to multiple epitopes 
maximizes the chances of the sandwich formation). Finally the conjugation/immobilization chemistries, 
stability and cost should also be considered for each assay development. For example a bioreceptor may 
not be compatible with the chosen nanoparticle (i.e. the absence of functional groups for its conjugation), 
thus forcing the developer to use it as capture bioreceptor. Or the immobilization of the bioreceptor on 
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the membrane leads to the unfolding of its structure and the loss of its functionality, while it may be 
compatible with the nanoparticle surface. Or the amount of bioreceptor needed for conjugation to the 
nanoparticle is considerably higher than the amount needed for its immobilization on the test line, so it 
behoves using the cheaper bioreceptor as detection bioreceptor.  
The characteristics for the control line capture bioreceptors are less stringent, since they have to bind 
either the detection bioreceptor or other molecules on the nanoparticle surface. In the case of using as 
detection bioreceptor an antibody, the control line capture bioreceptor could be a secondary polyclonal 
antibody. Instead if the detection bioreceptor is a nucleic acid the control line capture bioreceptor could 
be its complementary sequence. Other options such as biotin/streptavidin, BSA/anti-BSA antibodies and 
similar can also be employed for the generation of the control line.       
Table 2: Common bioreceptors used in LFA for the detection of protein targets. 




 Fast production 
 Multiple binding sites 
 Low specificity 
 Cross-reactivity 
 Variability between 
different batches 
Affinity purification of the 




 High specificity 
 Low batch-to-batch 
variability. 
 Expensive 
 Long development 
process. 
For immune-sandwich 
assays antibodies binding 
to different epitopes must 




example a membrane 
protein on the surface of a 
cell.  
Fragments  Less nonspecific binding 
 Once the sequence is 
known they are 
generally cheaper and 
easier to produce than 
full size antibodies 
 Low batch-to-batch 
variability 
 Ability to increase the 
number of bioreceptors 
per probe 
 Less stable than full 
length antibodies since 
they lack of Fc region 
Antibody against IgG Fc 
region cannot be used in 
control line. 
BSA should not be used as 
blocking agent, given its 
higher molecular weight 
(66 kDa) compared to the 
fragments (<50 kDa). 
The possibility to produce 
some of them as 
recombinant protein in E. 
Coli makes their synthesis 
easier and cheaper than 
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the immunization of full-
length antibodies or using 
human cell lines.  
Nanobodies  Less nonspecific binding 
 Once the sequence is 
known they are 
generally cheaper and 
easier to produce than 
full size antibodies 
 Low batch-to-batch 
variability  
 Ability to increase the 
number of bioreceptors 
per probe 
 Production limited to 
Camelidae and Sharks 
species. 
 
BSA should not be used as 
blocking agent, given its 
higher molecular weight 
(66 kDa) compared to 
nanobodies (15 kDa). 
 
 
Aptamers229  Cheaper than 
antibodies. 
 Ability to recognize any 
type of target analyte. 
 High stability 
 High batch to batch 
reproducibility 
 Their binding activity is 
highly dependent on 
the ionic strength of the 
buffer and the presence 
of interfering molecules 
in the buffer (i.e. certain 
cations) 
It is recommended to 
perform a denaturation 
and refold step before 
fabricating the LFA. 
 
 
Selecting nanoparticles for detection 
In recent years the development of new nanomaterials has broadened the type of labels available for LFA 
although mostly gold nanoparticles and latex beads are used in mass-manufactured tests (Figure 2).70–75 
Here, we describe what we think are the most relevant nanomaterials in regards to their type of readout 




Figure 2 – Examples of optical read outs of LFAs using different types of nanoparticles. In particular the 
figure shows calibration curves obtained for different targets (so non-comparable to each other in term of 
sensitivity) using nanoparticles providing an absorbance signal - A) gold nanoparticles,54 B) carbon 
nanoparticles,55 C) magnetic nanoparticles56 - and others generating a fluorescence signal - D) quantum 
dots,57 E) upconverting nanoparticles,58 F) fluorescence-loaded liposomes.59  
 
Naked eye detection. The use of particles that allow for naked eye detection in LFAs are particularly 
beneficial for qualitative applications or those that aim for cost effectiveness, i.e. not requiring the use of 
external readers. Nonetheless, coupling these particles with an external reader may increase the 
reproducibility and provide the quantitative analysis required for more challenging applications.  
- Gold nanoparticles: Since the 1980’s,76–78 gold nanoparticles (AuNPs) have become the most 
widely used detection labels in LFAs. The reasons behind their popularity are that (1) their surface 
plasmon resonance produces a strong red colour ideal for naked eye detection;79 (2) there are 
different synthetic methods that are able to produce AuNPs with different sizes and shapes; 80,81 
(3) they have low toxicity; (4) they can be easily functionalized either by nonspecific 
adsorption19(see Box 1 Steps xx-yy) or via covalent bonds, 82–85 and (5) they are relatively 
stable. Given that AuNPs are the most common labels in LFAs, in this manuscript (see Box 1 Steps 
XX-yy)  we propose an easy-to-optimize functionalization protocol. In addition, we also provide a 
step-by-step procedure for qualitative (by naked eye) and quantitative (camara-based) detection 
of an AuNPs-based LFA (see Box 1 Steps xx-yy). 
- Carbon-based materials: Recently carbon nanoparticles (CNP)86–92 and carbon nanotubes 
(CNT)93,94 have provided an alternative to AuNPs. Although they do not have a plasmon resonance 
that provides such strong signal as AuNPs, being black offers a stronger contrast to the white 
background of the nitrocellulose. In addition, they are cheaper to produce, less prone to 
aggregation and are easy to functionalise.  
- Dye loaded Latex beads: Another alternative to AuNPs are dye-loaded latex beads, as they are 
cheap and can be purchased in a variety of different colours. 2,95 Additionally, they are less 
sensitive to chemical and physical damage. 96 However, they are more suitable for qualitative 
assays and clinical screening, since their limit of detection tends to be higher in comparison to 
AuNPs. 97 
 
Fluorescent reading. The use of fluorescent labels is generally recommended for the detection of low 
target concentrations and/or application requiring quantitative results. However, this comes with a higher 
cost and the need for an external reader. Examples of suitable fluorescent nanoparticles are: 
- Quantum Dots: In fluorescence based LFAs, quantum dots (QDs) are typically the most used 
labels.98 When excited with UV light, they provide strong photoluminescence, whose emission 
peak can be tuned by changing the elemental composition and size of the QD. This also makes 
them ideal for multiplexed detection.99–102 In addition, they can be easily conjugated to 
bioreceptors103–106 and provide higher stability and resistance to photo-bleaching than organic 
dyes. 107 Nonetheless, their elemental composition may be toxic, their cost is generally higher 
than AuNPs and they require an UV-lamp for excitation. 98,108–110 
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- Upconverting nanoparticles: Since the early 2000s, upconverting nanoparticles (UCNPs) have 
been applied as labels in LFAs.111–113  Their excitation wavelengths, which is in the near infrared 
range, do not produce auto-fluorescence of the membrane (which occurs when illuminated with 
UV light) and their strong emission in the visible region produces more sensitive LFAs than those 
obtained using QDs.114 However, the need for an expensive and bulky near infrared laser is not 
appropriate for many PoC applications, thus limiting the integration of UCNPs in LFAs. 114–117 
- Liposomes: In an effort to increase the sensitivity of LFAs, the possibility to encapsulate 
fluorescent dyes into liposomes has also been explored. Besides carrying a high number of 
fluorescent dyes with the capability of producing a strong fluorescence signal, the possibility to 
tailor the lipid bilayer composition allows for the ease of functionalization of the liposome surface 
with bioreceptors. 118–121 However, the two main limitations faced with liposomes as labels in LFA 
are the complex synthesis techniques and poor stability.  
 
Non-optical readings. LFAs with non-optical readout are also possible and their use is comparable to that 
of fluorescence LFAs.122,123 In fact, lower detection limits and more quantitative results can be achieved in 
comparison with fluorescence-based LFAs, but they require specific readers. Examples of nanoparticles 
suitable magnetic and thermal readings are: 
- Magnetic nanoparticles: Magnetic nanoparticles (MNPs) are versatile labels for LFAs, since they 
provide both an optical and a magnetic signal. Their dark colour allows for their use as classical 
optical labels and their magnetic field can be harnessed for easier functionalization (e.g. removing 
unbound bioreceptors without the need of centrifugation), for sample pretreatment (MNPs could 
be incubated with the sample and separated prior their incorporation in LFA to remove any 
contaminant)124 and to provide a sensitive read out. In fact, while optical readouts rely mostly on 
the labels close to the surface of the membrane, measuring the magnetic field allows for the use 
of all the labels accumulated on the test line. 71,125–132 
- AuNPs for thermal reading: There are few reports about the implementation of thermal methods 
on LFAs, which are based on the thermal radiation emitted by AuNPs after being excited by a 
laser. This strategy can be exploited in order to achieve lower limits of detection where 
colorimetric measurements cannot reach. Moreover, thermal contrast readings are highly 
reproducible over time with the same LFA strip. The main limitations of thermal contrast 
techniques are the need for both a laser and an infrared camera. Nonetheless, recent efforts have 
been dedicated to the improvement of the portability of such setups.133,134 
- Nanoparticles for electrochemical readings: The use of an electrochemical output in an LFA can 
provide a variety of amplification strategies and a quantitative output.135–137 Although there are 
just few examples of this type of readout (especially those employing nanoparticles as 
electrochemical labels) in LFAs we believe they will be more frequent during the next years.135,138 
In our opinion, the reasons behind their limited spread so far is the increased complexity in the 
fabrication of LFAs. In fact, although there is a variety of techniques that can be used (screen-
printing, inkjet-printing, writing, pressing)139–141 for the modification of membranes with 
electroactive materials, they still imply extra steps and reagents during the fabrication process. In 
addition to the required dedicated reader.  
 
Table 3: Common labels used in LFA and their advantages and disadvantages.  
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LABEL ADVANATGAGES DISADVANTAGES 
AuNPs  Qualitative naked-eye detection 
 Well-known conjugations 
 Strong signal 
 
 Quantitative detection requires extra 
hardware 
 Relative expensive if commercially bought 
CNPs/CNTs  Qualitative naked-eye detection 
 More stable 
 Cheaper than AuNPs 
 High signal-to-noise ratio 
 Quantitative detection requires extra 
hardware 
 Unspecific adsorption 




 Qualitative naked-eye detection 
 Resistant to chemical and physical 
damage 
 Cheaper than AuNPs 
 Multiple colours available 
 
 Quantitative detection requires extra 
hardware 
 Less sensitive 
 Weaker signal than AuNPs 
 
QDs  Strong fluorescent signal 
 Multiple colours available 
 
 Requires extra hardware (UV-light and reader) 
 Higher toxicity 
UCNPs  Strong fluorescent signal 
 No UV source necessary 
 Multiple colours available 
 
 Requires extra hardware (NIR laser) 
 More expensive than QDs (they are made of 
rare materials) 
 
Liposomes  Loading of multiple labels 
 Easy conjugation 
 
 Require extra hardware depending on the 
loaded label 
 Delicate to pH and ionic strength 
 
MNPs  Dual magnetic/colorimetric signal 
 High signal to noise ratio 
 Very sensitive 
 Possibility to incorporate sample 
pre-treatment and analyte pre-
concentration 
 





 Dual thermic/colorimetric signal 
 High signal to noise ratio 
 Very sensitive 
 





The sample pad represents the portion of an LFA where the sample is loaded at the beginning of the test. 
This component has two key functions: (1) assuring an even flow and (2) the standardization of the buffer 
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conditions of the sample. The material and design chosen for the sample pad can have a major influence 
on the overall system.18–20,142 
Characteristics of sample pads. The geometry and characteristics of the sample pad are important for the 
control of the sample flow and for the design of the final product (it will affect the shape of the housing 
cassette). In particular, the key parameters are: 
- Bed volume: The bed volume, or void/dead volume, refers to the volume of air contained within 
the sample pad. This parameter can be used to calculate the total amount of liquid that is required 
to wet the pad. It controls the volume of sample that flows to the rest of the LFA and is directly 
proportional to the thickness, porosity, and overall dimensions of the pad:  
 
Bed Volume = Total Volume of the pad * Porosity (%) 
 
For example, for a pad measuring 5 cm long, 0.5 cm wide, and 0.015 cm thick, with a porosity of 
70%, the bed volume would be: 5 cm * 0.5 cm * 0.015 cm * 0.7 = 0.02625 cm3 = 26.25 µL. We 
recommend for micron-size analytes (i.e. cells, bacteria), sample pads with high bed volumes (for 
example woven meshes) must be used to ensure the analyte is not trapped and retained within 
the sample pad. Instead for analytes at the nanoscale (i.e. proteins, toxins, nucleic acid), a 
commitment must be set between speed and sensitivity. 
 
- Thickness: The thickness of the pad not only influences the bed volume but also affects the 
consistency of the flow. For example, a thicker sample pad provides higher buffering capabilities 
and therefore a slower and more stable flow. A slower flow generally produces a higher sensitivity 
of the LFA by increasing the probability for the successful biorecognition of the target by the 
labelled bioreceptor. A thick pad may also be compressed by the housing cassette, leading to a 
decrease in the amount of sample absorbed and a reduced flow speed. On the other hand, thin 
sample pads require less sample volume, but have lower buffering and faster flow speeds, which 
may negatively affect the wetting of the following pads and decrease the sensitivity of the test. 
We recommend …. 
- Absence of extractable material: During the fabrication of the sample pad, manufacturers may 
include chemicals (referred as extractable material) to confer particular properties to the 
material. For the design of an LFA it is important to verify that there is no release of unwanted 
chemicals that may affect the flow or the biorecognition of the target. 
- Particle Retention Rating: The particle retention rating refers to the particles size that the sample 
pad is able to remove, allowing a proper filtration of the sample. If the chosen sample pad does 
not provide the desired particle retention rating, it is possible to incorporate an extra pad, for 
example blood filtration membranes. 
 
Types of sample pads. There are two main types materials used in commercially available sample pads: 
cellulose fibres and woven meshes. Sample pads made of cellulose fibres tend to be thicker (≥ 250 µm) 
and cheaper, but are also weaker for handling, especially when they are wet (making the fabrication more 
delicate). They typically have bigger bed volumes (≥ 25 µL/cm3) and have higher tolerance towards the 
chemicals present in the sample pad buffer. Sample pads made of woven meshes, such as glass fibres, 
have good tensile strength and enable even distribution of the sample over the conjugate pad. In addition, 
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woven meshes can also act like a filter for removing particulates from the sample (for example Whatman 
LF1 and GF/DVA made of glass fibre,143 Whatman Fusion 5144 made of a PVA-coated glass fibre, and the 
Pall Vivid Plasma Separation membrane145 made of asymmetric polysulfone), avoiding the blockage of 
further pads in the remaining LFA, and are able to retain minimal amounts of sample, thanks to their low 
bed volumes (≤ 2 µL/cm3). On the other hand, they tend to be more expensive, are sometimes more 
difficult to cut than cellulose fibres and can be affected by chemicals used during the fabrication.  
 
Sample pad buffer and preparation. In addition to filtering out impurities, the sample pad corrects the 
sample composition by adding regents that confer the appropriate pH, ionic strength, viscosity and 
blocking capabilities. In order to achieve this, the sample pad is generally soaked in a dedicated buffer and 
further dried, prior its application in the LFA strip. Looking at the sample pad buffer composition, we can 
find four main components: 
- Buffering agents: The type and concentration of buffering agents will determine the pH and ionic 
strength of the solution for the whole duration of the assay. This affects not only the 
reproducibility of the assay (by creating the same conditions for different samples), but also the 
sensitivity and specificity of the test itself (pH and ionic strength can affect the interaction 
between the receptor and target as well as nonspecific binding, this should also be considered for 
other buffers used in the LFA, such as the running or washing buffers). The most used buffers are: 
phosphate (pH range between 5.8 and 8),146,147 TRIS (pH range between 7.5 and 9),148,149 HEPES 
(pH range between 6.8 and 8.2)150 and borate (pH range between 8 and 10).151 Their concentration 
depends on the specific application, but it generally varies between 10 and 100 mM, where higher 
concentrations are used for more complex and variable samples.   
- Detergents: The use of detergents in the sample pad buffer has two main functions: (1) minimizing 
the nonspecific binding (disrupting weak ionic and hydrophobic bonds) and (2) facilitating the flow 
of the detection labels along the different pads. Common detergents used in the sample pad are 
SDS (concentration ranging between 0.05 - 0.5% (wt/vol)), Tween® 20 (concentration ranging 
between 0.01 and 0.1% (vol/vol)) and Triton (concentration ranging between 0.05%-1% (vol/vol)).  
- Blocking agents: Together with detergents, the use of blocking agents in the sample pad buffer 
can minimize the formation of nonspecific bonds, making the LFA more specific. Furthermore, by 
adding the blocking agent onto the sample pad, blocking of the membrane may not be required, 
making the overall fabrication easier and faster. The most common used blocking agents are BSA 
(concentration ranging between 0.01 and 0.1% (wt/vol)), milk (concentration ranging between 
0.01 and 0.1% (vol/vol)) and casein (concentration ranging between 0.1 and 2% (wt/vol)). 
Chaotropic agents, such as polyvinyl alcohol (concentration ranging between 0.1 and 1% 
(vol/vol)), polyvinylpyrrolidone (concentration ranging between 0.3 and 1% (vol/vol)) and 
polyethylene glycol (concentration < 0.5% (vol/vol)), are sometimes also added into the sample 
pad buffer to prevent non-specific interactions, however this strategy is less commonly used.152   
- Preservatives: Finally, preservatives such as sodium azide (concentration ranging between 0.01-
0.05% (wt/vol)) could be used in commercial tests to avoid microbial contamination on the LFA 
strip. 
 
Generally, the drying of the sample pad follows a less delicate procedure than that for the drying of the 
conjugate pad or the membrane. This is mainly due to the absence of delicate reagents, such as antibodies 
and nanoparticles, in the sample pad. The most common drying method is placing the sample pads in an 
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oven at 37 °C, but this can be increased to 45-60 °C. Alternatively, the sample pads can be dried by vacuum 




The conjugate pad is the second pad to be encountered by the sample encounters. It has three main 
functions: (1) preserving the dried conjugated nanoparticles for detection, (2) releasing them upon 
wetting by the sample and (3) providing the first interaction between the labelled bioreceptor and the 
target. Given its key role in the LFA, preparation of the conjugate pad is one of the most critical stages 
during fabrication of the device. Overall the conjugate pad should provide low nonspecific binding (to 
avoid the retention of the nanoparticles or the target into the conjugate pad), a consistent flow and bed 
volume (achieving an homogenous and reproducible flow along the width of the membrane is essential 
to obtain reproducible results), and mechanical strength without extractable material (the conjugate pad 
must resist the fabrication process and the housing without releasing any material that can block the 
membrane or interfere with the signal generation). 18–20,142  
Types and characteristics of conjugate pads. The most used material for the conjugate pad is glass fibre; 
although cellulose and polyester can also be used. The choice of the conjugate pad material should take 
into account several factors such as thickness, bed volume and resistance to nonspecific binding. In 
particular cellulose pads provide the higher thickness (300-1000 µm), followed by glass fibre (100-500 µm) 
and polyesters (100-300 µm). As mentioned for the sample pad, a thicker material generally means a 
higher bed volume (assuming similar pore size). This in turn allows for the storage of a higher amount of 
nanoparticles for detection, a slower flow, and a higher sensitivity. At the same time, it is also related to 
a weaker mechanical strength of the material when it is wet.    
Conjugate pad buffer and preparation. The conjugate pad buffer functions to maximize the stability of 
the particles and to completely release them upon re-wetting by the sample. In the conjugate pad buffer 
composition, we find two main components (besides the particles): 
- The buffering agents: Given that most nanoparticles used for detection in LFAs are colloidal 
suspensions, their stability is generally affected by the ionic strength of the solution. Considering 
that the nanoparticles will undergo a drying process during the fabrication of the LFA (which 
produces a temporary increase in the salt concentration), it is recommended to start with a low 
ionic strength. For example, one of the most common buffers used for this purpose is borate 
buffer at 2-5 mM. It is important to note that, during the assay, it is the sample pad buffer that 
has the major role on the buffering of the overall test. 
- Stabilizing and re-solubilisation reagents: The key components of the conjugate pad buffer are 
sugars, in particular sucrose and trehalose. They have two main functions: preserving the native 
conformation of dehydrated proteins (the hydroxyl groups of sugar molecules replace the water 
around the protein upon drying) and their quick re-solubilisation upon wetting.153 Typically, they 
are used at concentrations ranging from 1 to 10% in volume.154   
 
Once a suitable buffer has been chosen, the bioreceptor-nanoparticle conjugate can be loaded into the 
membrane by either air jet dispensing or by immersion process. Air jet dispensing is the most reliable non-
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contact method to deliver the particles, as it provides quantitative coverage all over the membrane. The 
immersion method, on the other hand, is used when the air jet method is not possible, however, the 
major drawback is that the coverage is not uniform and may lead to high sensor to sensor variability.155 
 
The drying process is crucial to maintain the stability of the dried bioreceptor-nanoparticle conjugate and 
determines the release efficiency from the membrane. For example, failing to completely dry the 
conjugate pad may generate a syrup like solution unable to run through the membrane. There are two 
ways to dry the conjugate pad upon loading: hot air and vacuum drying.19 For mass production of LFAs, 
hot air is the most convenient method (given its ability to process a high quantity of conjugate pad and 
lower cost) and is typically fixed at 37 °C to not affect the stability of the bioreceptors.34,156 In smaller 
laboratories or when mass production is not required, vacuum drying may be the preferred method as it 
is not a heat-induced drying process and therefore does not affect the stability of the bioreceptors 




The membrane (also called detection pad) is the part of the LFA strip where the signal is generated. The 
key characteristics of the membrane are that it should (1) facilitates a homogenous flow, (2) provide a 
solid functionalization for capturing the bioreceptor and (3) show low nonspecific binding.  
Types and characteristics of the membrane: Commercial membranes are generally defined by their 
capillary flow time, which is the time required for the sample front to cover the membrane length 
(generally 4 cm), and is generally expressed as sec/4cm. A few manufacturers classify their membranes 
based on their pore sizes, and, in that case, the conversion of pore size to capillary flow time is roughly: 8 
µm = 135 s and 6 µm = 180 s. In general, the higher the capillary flow time, the slower the flow speed. 
This parameter is crucial not only for the overall duration of the assay, but it has a fundamental role in 
defining the sensitivity and specificity of the LFA. High capillary flow times allow for a longer interaction 
time between the target molecule and the bioreceptor, thus increasing the sensitivity of the test.157 At 
the same time, high capillary flow times also increase the chance for nonspecific binding to happen. 
Therefore, it is crucial to evaluate the membranes, with particular attention to the different capillary flow 
times, during the development of an LFA.  
The membrane material defines the type of interactions that govern the functionalization of the 
membrane with the capture bioreceptors (both for the test and control lines). Nitrocellulose is the most 
commonly used membrane due to its low price, its strong binding to proteins (including antibodies, the 
most used type of bioreceptors) and its tuneable wicking properties (obtaining different capillary flow 
times and the possibility to change surfactant content).158 Regarding the other types of membranes 
polyvinylidene fluoride (PVDF) is mainly used for water filtration and western blot thanks to its broad 
solvent compatibility, low background and superior staining capabilities.159 Similarly, nylon is also mainly 
used for filtering aqueous and organic solutions thanks to being strong, flexible, hydrophilic and solvent-
resistant.160,161 Finally, polyethersulfone (PES) thanks to its hydrophilicity and extremely low protein 
binding, is generally used to remove micro/nanoparticles, bacteria, and fungi from the sample.162 
Immobilization buffer. Overall, membrane functionalization with the capture bioreceptor occurs via non-
covalent binding (for example, for nitrocellulose, there are mostly electrostatic and hydrophobic 
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interactions),163 and as such, it is important that the immobilization buffer is optimized accordingly. In this 
respect the immobilization buffer has to maximize the capture bioreceptor adsorption on the membrane, 
maintain the capture bioreceptor reactivity and not alter the flow properties of the membrane. Looking 
at its composition in more details, we find four main components: 
- The buffering agents: The ideal buffer should maintain the stability of the capture bioreceptor and 
promote its binding to the membrane. For this reason, buffers with low ionic strength (10 mM) 
and a pH between +1 and -1 unit of the isoelectric point of the capture bioreceptor are preferred. 
Buffer compositions with high salt concentrations may screen the electrostatic interactions 
between the membrane and the capture bioreceptor. Additionally, slightly varying the pH from 
the isoelectric point of the bioreceptor assures for proper solubility without affecting its tertiary 
structure. The two most common buffers used for this purpose are ammonium acetate and 
phosphate buffers.  
-  Stabilizers: As mentioned for the conjugate pad buffer, the presence of sugars can help stabilizing 
the capture bioreceptor once the membrane is dried. For this reason, low concentrations of 
lactose (0.1% w/v) or trehalose (1% w/v) can be included and their concentration should be 
carefully optimized in order to avoid losing bioreceptor activity upon re-solubilization. 
- Alcohols: Alcohols are also included in the immobilization buffer due to their ability to reduce the 
solution’s surface tension, viscosity and static repulsion, enable faster drying times and improve 
the binding of the capture bioreceptor to the membrane. The most commonly used are methanol, 
ethanol, isopropanol at concentrations between 1% to 10% (v/v). 
 
Membrane Striping. The immobilization buffer composition and the membrane material define the type 
and efficiency of membrane functionalization with the bioreceptor. The striping strategy itself (i.e. the 
deposition of the bioreceptor into the membrane) is crucial to define the width of the test and control 
lines. As this is a fundamental aspect with respect to the reproducibility of the LFA, the striping should be 
performed using automated dispensers, allowing for precise control over the flow rate and the speed (so 
the deposition amount of bioreceptor), as well as the positioning of the lines onto the membrane. There 
are two types of automated dispensers: contact and non-contact. Although both types provide similar 
results, different precautions must be taken for each instrument. For contact dispensers, it is important 
to verify that the dragging of the nozzle does not produce indentations, or grooves, on the membrane; 
whilst for the non-contact method, the dispensing height should be optimized for membranes of different 
thicknesses.   
Looking in more detail at the striping process we find four main parameters: 
- Bioreceptor concentration: The capture bioreceptor concentration will determine the maximum 
signal achievable by the LFA. Intuitively, the more concentrated the bioreceptors on the test line, 
the higher the density of labelled nanoparticles is that can be achieved. In the case of immune 
sandwich assays (see Box 2), it is generally recommended to use an antibody concentration of at 
least 1 mg/mL in the dispensing solution (see Box 1 Step xx). For competitive assays (see Box 2), 
where the presence of target (often, but not limited to, small molecules presenting a single 
binding site – atoms, toxins, pesticides, peptides) decreases the signal, the capture bioreceptor 
concentration should be around 0.1 mg/mL up to 1 mg/mL. In this case (or if the capture 
bioreceptor is particularly expensive, or the use of a highly concentrated solutions is not feasible) 
it is often necessary to compensate the low bioreceptor concentration with a complementary 
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protein, such as BSA, in order to raise the overall protein concentration in solution. This 
precaution is necessary to maintain the structure and functionality of the bioreceptor over time, 
as a low concentrations can induce protein denaturing and loss of binding activity.  
- Flow rate and speed: The dispensing flow rate defines how much liquid is dispensed over time 
(i.e. how much bioreceptors-containing solution is dispensed), and is generally defined in μL/cm. 
The higher the flow rate, the large the dispensed volume (for a fixed area), and the wider the 
striped line will be. The speed defines the distance travelled by the nozzle over time, and is 
generally expressed in mm/sec. So, for a fixed flow rate, the slower the speed the higher the 
volume of bioreceptor-containing solution that is dispensed. During the fabrication of an LFA, the 
developer must optimize and balance these two values to obtain reproducible and well defined 
lines. Generally, it is preferred to obtain narrower lines since this allows the use higher 
bioreceptor concentrations and to be cost effective. For antibodies and assuming the use of a 
nitrocellulose membrane with average capillary flow time (120 sec/4cm), the starting parameters 
are typically 1 μL/cm for the flow rate and 20 mm/sec for the speed (see Box 1 Step xx). 
- Position and size: Besides affecting the geometry of the housing cassette (in particular the position 
of the reading window), the position of the test line also contributes to the sensitivity of the LFA. 
The further it is placed from the conjugate pad, the more time is allowed for the labelled detection 
bioreceptors and the target to interact, thus increasing the number of possible immune-
complexes to be captured onto the test line.164 The only requirement for the control line is that it 
must be positioned after the test line, since it should confirm successful flow of the sample front 
until the end of the strip. Usually, the test line is dispensed 12-13 mm from the origin of a 60 mm 
strip, while the control line is 4 mm behind the test line. In case of a multiplexed sensor, several 
test lines can be dispensed onto the same membrane, but there should always be at least a 2 mm 
spacing between them. For a deeper understanding on the best test line position we refer the 
reader to the work from Ragavendar et al.165 
- Drying: Similar to the conjugate pad, the presence of proteins (including antibodies) onto the 
membrane requires delicate drying, as high temperatures may denature the bioreceptors. The 
general conditions adopted are for 2 hr at 37 °C (see Box 1 Step xx).  
 
Blocking conditions. Although commercial membranes can generally directly be striped with the capture 
bioreceptors, in some cases it is necessary to further treat them with a blocking agent. However, generally 
speaking, blocking of the membrane should not be performed unless it is strictly necessary, i.e. when the 
blocking agents added to the sample or conjugate pad are not enough. Although blocking of the 
membrane decreases nonspecific signals, from a fabrication point of view, this step is quite cumbersome, 
requiring additional reagents, incubation and drying steps. and potentially affecting the flow of the 
sample. Consequently, this may affect the reproducibility and the overall analytical performance of the 
LFA. However, if blocking the membrane is required, it should always be performed after the striping and 
drying of the capture bioreceptors, otherwise the blocking agent hinders the functionalisation of the 
membrane. Common blocking agents are:  1-2% w/v BSA, 1-2% w/v IgG, 0.1-0.5% w/v gelatine, 1-2% w/v 
casein, 0.5-1% w/v PVP (8-10 kDa), and 0.1-1% w/v PVA (8 – 10 kDa). The choice of the blocking agent 
depends on the type of membrane, the sample and the capture bioreceptor. Generally, the blocking agent 
should be smaller than the capture bioreceptor, so not to induce steric hindrance that may affect its 
binding to the target analyte. PBS (0.01 M, pH 7.2-7.4) is the most commonly used blocking buffer. For 
blocking, the membrane is completely immersed in the blocking solution for 5-10 min and immediately 
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washed (at least twice) with a weak buffer (e.g. 5-10 mM PBS, pH 7.2-7.4 with 0.005%-0.01 w/v SDS) in 




The last pad in an LFA is the absorbent pad and its role is to control the volume of sample that a strip can 
take. In the absence of the absorbent pad, once the liquid reaches the end of the membrane, the flow 
stops and the liquid evaporates homogenously along the strip. This means that all the labels that did not 
reach the last part of the detection pad can accumulate on the strip and can increase the background 
noise.. On contrary, the presence of an absorbent pad assures that all the labels reach the end of the strip. 
A typical absorbent pad is … The absorbent pad does not require any special handling during LFA 
fabrication, and although its use is generally recommended, considerations such as its cost and its 
implementation in the LFA geometry (its incorporation requiring a housing cassette that is able to 
accommodate it) should be evaluated by the developer.18–20,142    
 
BOX 2: Types of lateral flow assays 
LFAs generally use one of the following two main sensing strategies: competitive or sandwich (non-
competitive) assays. Their successful use in LFAs requires the developer to consider important factors 
during the sensor design, fabrication and optimization.   
Competitive assays. There are two main types of competitive formats: In the first type, the target in the 
sample and a labelled-target (alternatively a molecule with less affinity for the bioreceptor than the target 
itself) in the strip compete for the capture bioreceptor on the test line,166,9. In the second type the target 
in the sample and the target on the test line compete for the labelled bioreceptor.150,167,168 A key 
characteristic of competitive assays is that a higher target concentration results in a lower signal. 
Competitive assays are generally used for small target molecules that cannot be efficiently recognized by 
more than one bioreceptor (such as drugs and toxins), but they could also be adapted for big analytes. 
Since competitive assays are not affected by the hook effect169 (the detection and capture bioreceptors 
have all their binding sites occupied by single targets, preventing the sandwich formation. This would 
show a low signal which may be mis-interpreted as absence or low target concentration), they are 
particularly useful for the detection of targets with extremely high concentrations. It is important for the 
developer of a competitive assay to verify that the bioreceptor can recognize the competitor molecule 
even after it is labelled or adsorbed on the membrane (the use of a spacer to anchor the competitor to 
the membrane or label may expose it and favour its recognition by the bioreceptor).  
Sandwich (non-competitive) assays. A sandwich (non-competitive) assay is probably the most used 
strategy for the detection of mid- and big-size analytes (such as proteins, antibodies, bacteria, cells) in 
LFAs. It functions by capturing the target molecule between a capture bioreceptor and a (nanoparticle-
)labelled detection bioreceptor, producing a signal that increases proportionally with the amount of target 
in the sample.34,170,171 One key aspect for the development of this type of assays is the requirement of two 
bioreceptors that bind different portions of the target. For example, two different monoclonal antibodies 
or a labelled monoclonal antibody and a capture polyclonal antibody are the most secure ways to ensure 
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the sandwich formation. In the case of particularly big targets, such as bacteria or cells, where the same 
antigen is repeated many times in the same target, the use of the same antibody (better if polyclonal) 
would also be a feasible option. As mentioned in the previous paragraph, sandwich assays are subjected 
to possible hook effects in the case of extremely high target concentrations169 and they are more prone 
to false positive results than competitive assays.  
- End of BOX 2 -  
 
Assembly of the LFA 
The assembly of the different pads and membrane on the strip is the final step prior to storing. Although 
sticking the pads and membrane on the supportive laminated card might seem trivial, it is actually an 
important step that will ensure the homogenous flow of the sample along the strip and the batch-to-batch 
reproducibility. The developer should assure contact between the sequential pads and their complete 
wettability to move all the reagents along the strip. Most laminated cards come with release liners that 
helps to position the different pads always at the same distance. This is convenient if the sizes of the 
different pads and the relative release liner are the same. There are also dedicated laminators 
commercially available, which would improve the consistency in the fabrication process. A detailed step-
by-step procedure for assembling a standard sandwich LFA is described in Steps xx-yy of Box 1.  
Finally the LF strip may be inserted in the housing cassette. It is possible to purchase pre-made housing 
cassettes from most of the pads/membrane providers, although in this case the width of the LF strip must 
be adapted to the width of the cassette (this assuming that the length and height are compatible given 
that they are produced by the same company). Alternatively LFAs with non-common geometries (for 
example using materials from different providers, or having dimensions non compatible with the 
cassettes) or requiring special functionalities (i.e. the application of the sample and a running buffer at 
different positions of the LF strip or requiring the docking of the cassette to a dedicated reader) may 
require the design of a dedicated cassette. In this case we recommend to test different cassette 
geometries using a 3D printer, which provides the freedom to vary several parameters at a low cost. Once 
the developer finds the final design, the cassette can be mass produced by specialized companies. Overall, 
once designing a housing cassette, the developer should consider three main aspects. First, the cassette 
should keep the LF strip in place (i.e. preventing it from flipping over or moving inside the cassette), 
without compressing or damaging the pads/membrane (this would affect the flow of the sample). Second, 
the cassette should have the hole to apply the sample positioned in the bottom part of the sample pad, 
so to assure the flow of the majority of the sample towards the membrane. Third, the reading window of 
the cassette must allow the user or the reader to easily visualize both the control and the test line(s).     
 
Single membrane LFA. So far, we have described the materials and features of the different membranes 
in a typical LFA strip. Alternatively, there is one membrane marketed by GE Healthcare that simplifies the 
manufacturing process, as well as minimize the costs: FUSION 5.144 This unique glass fibre-based 
membrane with proprietary technology, facilitates the production of the LF strips, because it can adopt 
any of the roles of the different pads and membrane needed for a single LFA in just one single device. In 
general, FUSION 5 overcomes several problems when manufacturing LF strips such compatibility and 
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contact issues between the membranes. When working with complex samples such as blood, it can act as 
a separator, obtaining a serum with a similar yield compared to conventional centrifugation procedures 
within 1 min following application of the blood drop. It also can act as conjugate pad due to its composition 
and permanent negative charge, which enables the release of the conjugate to the detection pad. As 
detection membrane, FUSION 5 does not need to be blocked in order to avoid unspecific adsorption. Two 
major drawbacks of the FUSION 5 are the need for carrier beads to load the bioreceptors of the test and 
control lines, and its low capillary flow time (38 sec/4 cm, so a relatively fast flow compared with some 
nitrocellulose membranes), which may reduce the sensitivity of the test in comparison with other types 
of membranes. As of March 2020 we did not find any scientific manuscript describing the development of 
a LFA using solely Fusion5, instead we found references using Fusion5 as part of LF strips or more complex 
structures.172–179  
Non-conventional materials. Other interesting low cost alternatives to the conventional LFAs 
membranes, such as cotton threads, cellulose and glass capillaries have been described in the last years. 
For instance, cotton threads are attractive for LFA development thanks to their flexibility and wicking 
properties, which allow the control of smaller sample volumes.180–183 Cellulose fibers (i.e. paper) have 
been extensively used for microfluidic paper analytical devices and some for LFA, because of their 
ubiquitous availability, biodegradability, and patterning capabilities.184 Although, they are a convenient 
option for diagnostics performed in low-resource settings, their major drawback is the need of a chemical 
modification to guarantee the immobilization of bioreceptors. Finally, glass capillary tubes can also be 
used to take advantage of their transparency, smooth surface and chemical inertness. These 
characteristics make them especially useful to minimize the non-specific binding by contaminants present 
in the sample matrix.185,186 
 
Storage 
To ensure that the analytical performance of the LF strip remains constant over time and within different 
applications and environmental conditions, the storage conditions of LF strips play a vital role. There are 
three main components that can affect the stability of an LF strip: the bioreceptors, the membrane and 
the label.  
In most cases, the bioreceptor will be the limiting factor for the stability of the strips. Regarding 
bioreceptor stability we need to distinguish between stable DNA molecules, which also includes aptamers, 
from more delicate proteins, such as antibodies. If properly dried, DNA molecules can withstand a wide 
range of temperatures and storage conditions. To maximize the shelf-life of proteins, dry and cool 
conditions are required (4 °C inside sealed bags with desiccants).187 If other proteins are included on the 
strips  (e.g. BSA as blocking agent in nitrocellulose) the same storage considerations should be taken into 
account. Particularly delicate bioreceptors may also require the addition of stabilizers (such as sugars, 
proteins, agars and gelatines188) to the relative buffers (for examples whey would be striped together with 
the capture bioreceptor or included in the conjugate buffer). Also, it should be considered that some 
surfactants used on LF strips to improve the flow across the paper or the release of the label particles may 
reduce the life-time of the proteins. Secondly, the membrane itself has an expiration date. Deteriorated 
nitrocellulose shows a yellowish colour, produces a sour smell and might generate faint lines after 
performing the assay. To maximize its life-time, nitrocellulose should be stored in dry conditions and 
protected from direct light (i.e. in a zipper bag with dessicants). Finally, the stability of the detection label 
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often depends on the nature of the label itself: properly modified (e.g. coated with a blocking protein 
during conjugation) and dried particles in glass fibre should not have any stability issues, whilst enzyme-
based or dye-loaded particles labels may require refrigeration to preserve their activity. LF strips should 
not be frozen. 
 
Assay evaluation 
Qualitative evaluation. When thinking of an LFA, the first thing that comes to mind is the presence or 
absence of the line in a pregnancy test (Fig. 3A). This intuitive and qualitative analysis done by naked eye 
is the reason of LFA popularity and it is ideal for the discrimination between the presence or absence of a 
particular condition, such as pregnancy.  
Semi-quantitative evaluation. A different approach for reading an LFA by naked eye relies on the use of  
barcode style LFAs, where the number and the intensity of multiple test lines facilitate a semi-quantitative 
reading (Fig. 3B).189,190 These kind of strips can be of useful in three main scenarios: (1) when the 
concentrations of two or more analytes needs to be assessed (i.e. the user can observe and compare the 
signals obtained for the different analytes and quickly verify if any of the analyte has an higher/lower 
concentration than the other); (2) for the detection of a defined target concentration threshold (a 
measurable line appears if the concentration of analyte is at least at the threshold value); and (3) to group 
target concentrations into different categories based on concentration ranges (i.e. ranges of 
concentrations can be represented by using different lines). The latter scenario is useful for the detection 
of biomarkers which are of interest just above/below a defined concentration, such as E. coli in urine.  
Quantitative evaluation. In recent years the development of dedicated readers and smartphones have 
facilitated the quantitative analysis of LFA (Fig. 3C-D).191,192 In order to achieve quantification, the 
fabrication process must provide highly reproducible strips (i.e. the developers and test manufacturers 
must strictly assure that the LFA production is extremely rigorous, otherwise the test result can greatly 
differ from different batches of LFA) and an accurate calibration curve to be used as a standard. The use 
of a dedicated reader is still preferred to obtain accurate measurements, as it minimizes the effect of 
ambient light on the signal intensity (to obtain a proper quantitative result the measurement should be 
performed using the same light conditions as the original calibrate, therefore the need of a fully closed 
box with integrated light sources). Hybrid systems where a smartphone is coupled to a special support 
also provide excellent performances.193,194  
Multiplexed evaluation. The detection for several targets at the point of care is highly desirable, for 
example for drug screening, diagnosis of infectious diseases, monitoring of pesticides. Although the 
fabrication of LFAs for analysis of multiple target is particularly challenging (i.e. higher cost, longer 
optimizations, possible cross reactivity between biomolecules, etc.), there are some successful examples 
of this type of sensors. 3,195–201 In particular for a few number of targets (approximately under 10 different 
analytes), the read out could look like a barcode assay (where each line represents a specific analyte), 
instead for a high number of targets (over 10 different analytes), the read out would look like a microarray 
(where each dot represents a specific analyte). Overall the higher the line/dots to analyse the more 





Figure 3: Different types of read out of LFAs. A) Most LFAs are designed to give a qualitative (yes or no) 
response ideal for naked eye detection by non-specialized users (for example the pregnancy test). B) 
Similarly LFAs can also be designed to provide a semi-quantitative results. This type of reading is mostly 
limited to the fabrication of LFAs, when the developer needs to evaluate how different parameters affect 
the sensor response. C) The use of dedicated readers can make LFAs fully quantitative devices. Although 
most readers record an optical response, it is possible to have also magnetic and thermal readers. D) More 
recently smartphones are also being used as LFA readers (especially when coupled with an external 
platform to guarantee a constant lighting) or as user interface (receiving the LFA results via WiFi or 
Bluetooth). 
 
Iterative LFA development 
As described, an LF strip is comprised of a variety of materials and reagents that are carefully 
interconnected to produce a sensor that aims to be easy-to-use, yet still highly sensitive and specific. The 
most challenging and complex task during the development stage is tuning the different parameters and 
components to achieve the best sensing performance. Although there are groups working on 
computational modelling to facilitate the optimization of LFA,17,202,203 this approach is not yet widely 
implemented as it requires modelling and programming skills that are not always present in research 
groups or the availability of specific software.  
More generally, in research and development (R+D) laboratories, the optimization of an LFA relies on an 
iterative approach of trial and error, as described by Hsieh et al.16 As schematized in figure 4, the developer 
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first defines the analytical performance, usability and cost required by the specific application. Then, on 
this basis, there is the first screening (using standard techniques such as ELISA and SPR) of bioreceptors 
and analytes obtaining a shortlist of the most promising combinations. The resulting bioreceptors are then 
conjugated to the nanoparticles and the stability of the resulting conjugates is verified. At this point, 
developers use the half stick format (made of membrane and absorbent pad) to evaluate the 
combinations of membranes, blocking agents, running buffers, striping conditions and conjugates. If the 
original goals are met, developers use the 3/4 stick format (made of conjugate pad, membrane and 
absorbent pad) to evaluate the optimal preparation of the conjugate pad as well as the effect of the real 
sample matrix on the assay performance. Finally, there is the incorporation of the sample pad (and for 
commercial applications also the housing cassette) to evaluate the overall sensing performance. Although 
this approach for the LFA optimization heavily relies on trial and error, it is still time and cost efficient.  It 
is important to note, as we previously mentioned, that this is an iterative process, meaning that 
optimization steps might have to be repeated to compensate for changes done further down the 
optimization procedure. 
 
Figure 4: Ideal optimization route for the fabrication of a LFA. After setting the assay goal the developer 
should short-list the most promising bioreceptors using gold standard techniques (ELISA, SPR, BLI and ITC). 
The next step is the optimization of the conjugation to the nanoparticle label and the characterization of 
the conjugate stability (using UV-vis, TEM, DLS). Subsequently using a half-stick format (just membrane 
and absorbent pad) the developer can test several combinations of nanoparticles and bioreceptors to find 
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the most promising ones. During this stage there is also the first evaluation about the need to block the 
membrane. Then the developer employs a 3/4 stick format (half stick + conjugate pad) testing the 
conjugate pad fabrication and the effect of the real sample matrix. During this stage there is the second 
evaluation of membrane blocking. If the required sensitivity and specificity are met, then there is the final 
optimization using the full assay format (3/4 stick plus sample pad and housing cassette). During this phase 
the optimization of the sample pad buffer and eventually sample treatment strategies are evaluated prior 
using the housing cassette.       
 
Costs, patents and production 
The estimation of the cost of an LFA depends on the development phase of that particular test: R+D, large 
scale manufacturing or in the commercial market. During the R+D phase, most of the costs are attributed 
to the bioreceptors used in the LFA. Generally, we estimate the production costs of a single LF strip to be 
less than 1 $ (see Supplementary Table 1 for a detailed example). Despite this low cost, a R+D project for 
developing a novel LFA could require a lot of financing: labware, consumables, paper, chemical and 
biological reagents (around 30,000-40,000 $/year); new equipment and maintenance (around 60,000 $); 
laboratory renting, personnel and over costs (depending on the location, size, employee degree, country, 
etc.); subcontracting (e.g. materials characterization, regulatory control, legal advice and patentability); 
taxes and travels (project meetings, congresses and assay demonstrations). This cost will vary depending 
on the current status of the facilities, the project and the milestones. The main objective of an R+D phase 
should be to reach a minimum viable product (MVP), that is an LFA that has demonstrated to have enough 
repeatability (same response reproduced from the test over time), replicability (same response applying 
the LFA in different environments) and reproducibility (same response when different operators 
reconstruct the design), and that clearly differentiates and defines positive and negative responses. Then, 
with a reliable MVP, the next costs will come from proprietary and regulatory expenses.  
In this regard, patentability of a relatively old technology such as LFA can be challenging, as for the patent 
to be accepted there should be a demonstrable and non-obvious novelty. Generally, the patentability can 
come from one or more of the following points:  
- Biomarker – an LFA detecting a new biomarker, whose presence or absence is related to a specific 
disease or status.  
- Bioreceptor – an LFA using a new bioreceptor for a defined application (for example an aptamer 
sequence). 
- Label – an LFA using a new label implying a new detection method, sensing strategy or a signal 
enhancement. However, nanomaterial size modifications, new dyes or conjugation of enzymes 
on the surface of the label are often not enough to be considered as novel ideas.  
- Sensing strategy – an LFA using a new sensing mechanism that leads to a demonstrated advantage 
over a standard assay. It may include extra steps, reactions or interactions between the different 
pads, labels and biomarkers. 
- New materials – an LFA using new materials as pads or membrane, instead size modifications on 
the pads and parameters such as porosity and protein affinity are difficult to protect.  
- New Design – an LFA that employs a new functionality or has an identificative trademark. 
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Patenting processes are long (more than one year in most cases) and the costs are generally high 
(evaluation and certifying costs), leading also to maintenance costs. The patent cost will also vary 
depending on the level of protection of the technology (country-wide, continent-wide or world-wide). In 
addition to the requirements of each country in which the LFA will be used, regulation and approval (see 
next section) expenses will also depend on the target user and environment. During this phase, the R+D 
laboratory will still be in charge of producing and providing the product for its evaluation. 
After R+D, with the MVP protected and approved for the market, the next phase is the mass production. 
During the mass production in a factory, the cost per LF strip decreases to about 0.01 $, although this does 
not include equipment and their maintenance, the employees, insurances, taxes, quality controls and 
many other indirect costs. Finally, the market cost is the toughest one to estimate. For the sake of 
comparison, we will use the cost of “Clearblue Rapid Detection Pregnancy Test”, which we can purchase 
for approximately 6 $ per test. Although it could seem that there is a great benefit for the company and 
the seller, there are also even more indirect costs such as: packaging (cassettes, bags, desiccants etc.) and 
storage of the product, shipping, marketing, taxes, additional reagents and tools, plus the cost of R+D and 
clinical validation that need to be taken into account.  
 
Regulation and approval 
An LFA for the purpose of PoC, or clinical environments, is considered a medical device and its use is 
regulated by governmental institutions such as the European Medicines Agency (EMA) in EU or the Food 
and Drug Administration (FDA) in US. In the EU, medical devices have to undergo a conformity assessment 
to demonstrate that the legal requirements are met to ensure they are safe. Accredited national 
authorities are responsible to conduct these conformity assessments that, once fulfilled, award the device 
the CE (“Conformité Européenne”, tr. European Conformity) mark. 
Furthermore, LFAs also work as in vitro assays, where the device does not affect the organism in which it 
interacts with. In this case after obtaining the MVP and, in order to obtain the CE mark (or the regional 
corresponding indicator), the device should be validated as indicated by the relevant institution. 
Depending on the origin of the samples, an ethical committee may have to evaluate the process. 
 
Future Directions 
LFAs have been some of the most popular biosensors for the past decades and we believe they still have 
a bright future ahead, especially if developers will design them to address the challenges that 
personalized/precision medicine and in-the-field environmental analysis will present. Regarding clinical 
purposes, we believe there are two major goals that the next generation of LFAs should tackle: (1) the 
sensitive and quantitative detection of multiple protein targets at under pM concentrations3,195–199 (for 
example using a microarray-type approach)204  and (2) the integration into a single LFA strip of both a 
nucleic acid amplification and detection.205–211 Similarly, for environmental analysis an improvement in 
the sensitivity and quantitative ability of multiple targets will be required, together with the 
development of LFAs detecting families of compounds rather than specific molecules. Succeeding in 
these tasks will require a joint effort between different disciplines, ranging from the selection of 
bioreceptors showing desirable characteristics  for LFAs (fast binding kinetics and stability), to the 
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development of novel materials showing superior properties (either labels or new membranes, pads, 
and filters212), to the use of programming to optimize the fabrication of LFAs and their quantitative 
analysis using portable readers.    
 
BOX 1: Example protocol for a lateral flow assay to detect human IgG 
This Box describes a detailed step-by-step procedure for a traditional sandwich LFA to detect human IgG. 
In this example, we use two different polyclonal antibodies as capture and detection bioreceptors, the 
latter one being coupled to gold nanoparticles for qualitative detection by the naked eye and quantitative 
camera-based detection. Before assembling the LF strip, we provide a detailed procedure to screen for 
optimal buffers to reduce aggregation of the AuNP-bioreceptor conjugates. Troubleshooting guidance is 




- Capture bioreceptor for the test line. In the example shown in this protocol we use an Anti-Human 
IgG (whole molecule) antibody produced in goat (Sigma-Aldrich, Cat. no. I1886) 
(RRID:AB_260125). 
- Capture bioreceptor for the control line. In the example shown in this protocol we use a Chicken 
Anti-Goat IgG H&L (Abcam, Cat. No. ab86245) (RRID: AB_1951137). For general recommendations 
on how to select and validate control line antibodies, see … of the main text. 
- Detector bioreceptor for conjugation to AuNPs . In the example shown in this protocol we use an 
Anti-Human IgG (γ-chain specific) antibody produced in goat (Sigma-Aldrich, Cat. no. B1140) 
(RRID: AB_258513). 
- Target analyte. In the example shown in this protocol we use IgG from human serum (Sigma-
Aldrich, Cat. no. I2511) (RRID: AB_1163604). See in the main text for a detailed description of 
possible target analytes and samples. 
- Bovine serum albumin (BSA; Sigma-Aldrich, Cat. no. A3294) 
- AuNP solution (Gold nanoparticles 20nm, BBI Solutions, Cat. No. EM.GC20) 
- Hydrochloric acid, 37% (w/w) (Sigma-Aldrich, Cat. no. 320331)  
Caution: Hydrochloric acid may be corrosive to metals, causes severe skin burns and eye damage 
and may cause respiratory irritation. Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. Wear 
protective gloves/ protective clothing/ eye protection/ face protection. Handle it inside a fume 
hood. 
- Sodium hydroxide (NaOH; Sigma-Aldrich, Cat. no. S8045) 
Caution: Sodium hydroxide may be corrosive to metals and can cause severe skin burns and eye 
damage. Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. Wear protective gloves/ 
protective clothing/ eye protection/ face protection. Handle it inside a fume hood. 
- Sodium phosphate monobasic monohydrate (NaH2PO4·H2O, Sigma-Aldrich, Cat. No. 71504) 
- Sodium phosphate dibasic (Na2HPO4, Sigma-Aldrich, Cat. No. 71640) 
- Sodium tetraborate decahydrate (Na2B4O7·10H2O, Sigma-Aldrich, Cat. No. B9876) 
Caution: Sodium tetraborate decahydrate causes serious eye irritation, may damage fertility and 
may damage the unborn child. Obtain special instructions before use. Do not handle until all 
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safety precautions have been read and understood. Wear protective gloves/ protective clothing/ 
eye protection/ face protection. 
- Boric acid (H3BO3, Sigma-Aldrich, Cat. No. B7901) 
Caution: Boric acid may damage fertility and may damage the unborn child. Obtain special 
instructions before use. If exposed or concerned get medical advice/ attention. 
- Sodium citrate (HOC(COONa)(CH2COONa)2·2H2O, Sigma-Aldrich, Cat. No. 1613859) 
- Sucrose (C12H22O11, Sigma-Aldrich, Cat. No. 84097) 
- Phosphate buffered saline tablets (Sigma-Aldrich, Cat. No. P4417) 
- Tween-20 (Sigma-Aldrich, Cat. No. P1379) 
- MilliQ water (produced using Milli-Q system (>18.2MΩ*cm)) 
 
Equipment 
- Detection pad (mdi, Cat. No. CNPH200). 
- Backing card (Kenosha, Cat. No. KN-PS1060.45). 
- Sample and absorbent pad (Merck Millipore, Cat. No. CFSP001700). 
- Conjugate pad (GE Healthcare, Standard 14 Cat. No. 8133-2250). 
- Graduated pipettes (Gilson P2, 20, 200, 1000).  
- Tips for graduated pipettes (Fisherbrand, Cat. No. 10177190 and 10677731). 
- Polypropylene Graduated Microtubes (Eppendorf, 0030120248). 
- Transfer Pipettes (Fisherbrand, Cat. No. 13439108) 
- Lateral flow assay reader (Skannex, SkanMulti with OEM software). 
- ThermoShaker for microtubes (Biosan, Cat. No. TS-100).  
- Centrifuge (Beckman Coulter, Allegra 64R). 
- Reagent dispenser (Imagene Technology, IsoFlow reagent dispenser). 
- Programmable strip cutter (Kinbio, Cat. No. ZQ2002). 
- Oven (P. Selecta, Cat. No. 2001246) 
- Laboratory pump (KNF lab, Laboport Cat. No. N938.50KN.18) 
- Vacuum Desiccator (Karnell, Cat. No. 550) 
- pH meter (Crison, pH meter Basic 20+) 
- Analytical balance (Ohaus Discovery, Readability: 0.001 g). 
- Milli-Q system (>18.2MΩcm-1) (Millipore) 
- Fume hood (Flores Valles) 
- Fridge and Freezer (Premium NoFrost) 
Software 
- ImageJ - Version 1.52u - https://imagej.nih.gov/ij/ 
- OriginLAb – Version 8 - https://www.originlab.com/ 
- Excel – Version 2016 - https://products.office.com/en/excel 
 
Reagent Setup 
Phosphate Buffer Saline (PBS) (0.01 M; pH 7.4) Dissolve one PBS tablet in 200 mL of MILLIQ water. Store 
it at room temperature (25 °C) for up to 30 d. 
Phosphate Buffer (0.01 M; pH 7.4) Dissolve 0.21 g of Sodium phosphate dibasic in 150 mL of MilliQ water. 
Dissolve 0.20 g of sodium phosphate monobasic monohydrate in 150 mL of MilliQ water. Add a magnetic 
stirrer and measure the pH of the sodium phosphate dibasic solution under agitation using a pH meter. 
Add the sodium phosphate monobasic monohydrate solution dropwise to the sodium phosphate dibasic 
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solution with a disposable Pasteur pipette until the pH value reaches 7.4. Store it at room temperature 
for up to 30 d. 
Borate Buffer (10 mM; pH 7) Dissolve 0.58 g of sodium tetraborate decahydrate in 150 mL of MilliQ water. 
Dissolve 0.092 g of boric acid in 150 mL of MilliQ water. Add a magnetic stirrer and measure the pH of the 
sodium tetraborate decahydrate solution under agitation using a pH meter. Add the boric acid solution 
dropwise to the sodium tetraborate decahydrate solution with a disposable Pasteur pipette until the pH 
value reaches 7. Store it at room temperature for up to 30 d. 
Borate Buffer (100 mM; pH 9) Dissolve 5.72 g of sodium tetraborate decahydrate in 150 mL of MilliQ 
water. Dissolve 0.92 g of boric acid in 150 mL of MilliQ water. Add a magnetic stirrer and measure the pH 
of the sodium tetraborate decahydrate solution under agitation using a pH meter. Add the boric acid 
solution dropwise to the sodium tetraborate decahydrate solution with a disposable Pasteur pipette until 
the pH value reaches 9. Store it at room temperature for up to 30 d. 
Conjugate pad buffer Prepare a solution of PBS buffer containing 5% (wt/vol) sucrose, 1% (wt/vol) BSA 
and 0.5% (vol/vol) Tween-20. Store it at 4 °C for up to 7 days. CRITICAL: The sucrose and Tween-20 in the 
conjugate pad buffer are imperative for the release and flow of the conjugated AuNPs solution along the 
nitrocellulose strip.  
 
Sample pad buffer Prepare a solution of PBS buffer containing 0.5% (wt/vol) BSA and 0.05% (vol/vol) 
Tween-20. Store it at 4 °C for up to 7 days. 
 
Procedure 
The following simple procedure elucidates the optimal conditions to perform the functionalization of 
AuNPs with the detection bioreceptor. In particular it allows the definition of the optimal pH and the 
minimum antibody concentration to fully cover the nanoparticles. The procedure relies on the propensity 
of bare (citrate-covered using the Turkevic synthesis) gold nanoparticle to aggregate in the presence of 
high salt concentrations.213 Once the AuNPs are fully covered with the antibody (or with a blocking agent, 
such as BSA) they remain monodispersed even at high salt concentrations. The aggregation rate can be 
qualitatively assessed by naked eye: fully aggregated AuNPs induce a colour change of the suspension 
from red to transparent (due to their precipitation), partially aggregated AuNPs would change to colour 
of the suspension from red to blue (due to a shift and widening of their plasmonic peak), while 
monodispersed AuNPs should maintain the original red colour.214 This can be quantitatively measured 
using UV-vis spectra, DLS, Z-potential and TEM.  
Nanoparticle-bioreceptor Aggregation Test - 1 hour 
1. Prepare three solutions of 20 nm diameter AuNPs at pH 7, 8 and 9 (with OD of approx. 0.450 at 
520 nm). Set the correct pH with 10 mM borate buffer (for pH 7) and 100 mM borate buffer (for 
pH 8 and 9). 
2. Prepare dilutions of the detector bioreceptor (detector anti-Human IgG in this example) in MilliQ 
water (200, 175, 150, 125, 100, 80, 60, 40 and 0 μg/ml). Prepare a solution of 10% NaCl (wt/vol) 
in MilliQ water.  
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CRITICAL STEP – Although we typically use a 10% NaCl (wt/vol) solution for the gold aggregation 
test, it is possible to substitute it with a different buffer (e.g. conjugate pad buffer or LFA running 
buffer) to study their effects on the stability of the conjugates.  
3. In a 96 micro-wells plate put 150 μL per well of the AuNP solutions from Step 1. Prepare 2 rows 
of 9 wells for each AuNP solutions in order to create a duplicate test. 
4. To each well, add 10 μl of one of the detector antibody dilution from Step 2 in increasing order of 
antibody concentration (see figure 5). 
CRITICAL STEP – For easy comparison of the effect of the pH, the wells in each column should have 
the same antibody concentration.  
5. Place the plate on top of the Thermoshaker for 20 minutes at 600 rpm.  
6. Add 20 μl of 10% NaCl (wt/vol) solution to each well.  
7. Place the plate back on top of the Thermoshaker for 5 minutes at 600 rpm. 
8. Measure the absorption spectra (from 400 nm to 600 nm with at least 5 nm between each 
measurement). 
9. From each spectrum evaluate the peak intensity, peak position and spectra shape (see Fig. 5).  
CRITICAL STEP - The maximum absorbance peak of 20 nm-sized AuNPs is at 520 nm. If the AuNPs 
aggregate in the gold aggregation test, the absorbance peak will shift to the right and the peak 
becomes wider. The use of the optimum pH and antibody concentration will avoid the aggregation 




Figure 5 - Results of the gold aggregation test for 20 nm diameter AuNPs and anti-Human IgG. A-C) 
Photos of the resulting GAT. Even by naked eye it is clear the colour gradient following the anti-human 
IgG concentrations. D-F) Bar charts obtained subtracting the OD at 520 nm from the one at 580 nm. This 
analysis allows to estimate the minimum antibody concentration to give stable conjugates. The higher 
the calculated value the narrower the peak, indicating more monodispersed AuNPs. G-I) Spectra 
obtained for the different tested conditions, confirmed the bar chart results. It is important to note that 
the peak position for stable conjugates will be slightly shifted to higher wavelengths (in this case 530 nm) 
due to the increased hydrodynamic diameter of conjugates (AuNPs + antibody) compared to the one of 
bare AuNPs (in this case 520 nm).  
 
Large-scale nanoparticle conjugation to the detector bioreceptor– 1 hour and 20 minutes 
10. Transfer 1.5 mL of the AuNP solution with the optimal pH (as selected in Step 9) in an 2 mL 
Eppendorf tube. 
11. Add the optimised amount of detector antibody in MilliQ water to the AuNP solution.   
CRITICAL STEP - The starting antibody concentration is defined by the gold aggregation test, but 
it should be further optimized, generally reducing it. For example, in this case we are using a final 
concentration of 2.5 µg/mL detector anti-Human IgG, which is lower than the amount defined by 
the gold aggregation test (6.6 µg/mL, assuming the gold aggregation test value of 100 µg/mL) 
because it provides a lower background signal (Fig. 6). 
12. Incubate the antibody-AuNP mixture for 20 minutes at 650 rpm at room temperature using the 
Thermoshaker. 
13. Add 100 μL of 1 mg/mL BSA in MilliQ water  
CRITICAL STEP – BSA has three functions: it covers any surface area not filled in with the antibody, 
it helps with stability, and it prevents nonspecific adsorption. 
14. Incubate the mixture for 20 minutes at 650 rpm at room temperature using the Thermoshaker. 
15. Centrifuge the mixture at 14000 rpm (30053 g) for 20 min at 4 ˚C.  
CRITICAL STEP - Centrifugation is performed to remove free antibodies that may interfere with 
the sensitivity of LFA and multiple centrifugation steps may be required to ensure the complete 
removal of unbound antibodies. The centrifuge parameters are selected depending on the size of 
the AuNPs and volume used. During the centrifugation the solution tends to heat and this might 
affect the stability of the conjugated antibodies. It is therefore recommended to adjust the 
temperature to 4˚C. 
16. Resuspend the antibody-AuNP pellet in 500 μL of the conjugate pad buffer. 
CRITICAL STEP - The dilution factor of the conjugation solution should be carefully selected, as it 
will affect the dynamic range of the assay.  Although a more concentrated solution of AuNPs might 
provide better detection limits in LFAs, it may affect the flow as well as increase the cost of the 
sensor.    
PAUSE POINT: The antibody-AuNP conjugate can be stored at 4 ˚C. 
 
Lateral flow strip fabrication – 2 hours and 30 minutes 
 
17. Nitrocellulose membrane striping (Steps 17-26): Fill the reservoirs (test and control lines pumps) 
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of the lateral flow dispenser with MilliQ water and dispense 2100 μL MilliQ water (dispense rate 
of 5 μL/cm and a speed of 50 mm/sec) in order to clean the syringe, tubing and nozzles. 
CRITICAL STEP – Every lateral flow dispenser has its specific washing procedure. Consult with the 
equipment manual of the specific equipment for details.  
18. Empty the supply lines and the reservoirs. 
19. Prepare a 200 μL solution of 1 mg/ml capture antibody (capture anti-Human IgG in this example) 
and a 200 μL solution of 1 mg/ml of the control line antibody (anti-goat IgG in this example) in 
phosphate buffer. Add the control line antibody solution in the reservoir corresponding to pump 
for the control line and the capture antibody in the one corresponding to pump for the test line.  
CRITICAL STEP: The volume of the dispensing solution should be enough to strip the required 
amount of nitrocellulose membranes. Usually 100 μL should be enough for the preparation of a 
30-cm nitrocellulose membrane using a dispense rate of 0.5 μL/cm and a speed of 50 mm/sec in 
Step 22.  
20. Prime the pumps and the tubing until a drop flows out of the nozzles.  
TROUBLESHOOTING:  
21. Place the CN200 nitrocellulose membrane (previously attached to the backing card) on the 
vacuum table.  
CRITICAL STEP: The laminated card side corresponding to the absorbent pad should touch the rear 
of the table. The position of the nozzles must be manually adjusted in order to determine the test 
line and control line position in the nitrocellulose membrane.  
22. Setup the pump system by adjusting the dispense rate at 0.5 μL/cm and the speed to 50 mm/sec. 
23. Press Run to dispense the capture antibody solution from Step 19 onto the test line and the 
control line antibody solution onto the control line. 
CRITICAL STEP: Be sure that the dispensed solutions are homogeneous, as this will affect the 
assay’s results. Discard any membrane with faulty lines, see Figure 6.  
24. Fix the antibodies by drying the detection pad at 37 °C for 2 hours in the oven. 
TROUBLESHOOTING:  
25. (Optional) Block of the membrane with BSA: 
a. Soak the membrane into the blocking buffer (2% BSA, 0.01M PBS pH7.4) for 20 min; 
b. Soak the membrane into the washing buffer (0.05% SDS, 0.005M PBS pH7.4) with a gentle 
shake for 15 min. Repeat this step at least 2 times; 
CRITICAL STEP: It is crucial to remove the excess of BSA from the membrane otherwise, it 
may cover the binding site of the capture and control bioreceptors.  
c. Dry the membrane at 37℃ for at least 2 hour. 
 
26. Before turning off the lateral flow dispenser, perform washing procedure with MilliQ water, 
followed by 0.1 M HCl, 0.1 M NaOH and again MilliQ water. Remove the MilliQ from the tubing 
by un-priming the system.  
CRITICAL STEP: Dispense at least 10 syringe volumes during each washing step (dispense rate of 
5 μL/cm and a speed of 50 mm/sec). The pumps should be thoroughly cleaned monthly using a 
weak detergent (0.05% Sodium C14-16 olefin sulfonato), 10 % (vol/vol) bleach, HCL (0.01 M pH 





Figure 6 – Examples of how the AuNPs conjugation and the striping of the test line can affect the LFA 
signal. A) Using a concentration of 6.6 µg/mL (left) vs one of 2.5 µg/mL (right) of anti-Human IgG during 
the AuNPs functionalization produced different signal in LFAs challenged with a blank solution (all the 
other parameters in the LFA fabrication were fixed). In particular, the former produced a higher non-
specific signal (stronger red line) compared to the latter. Thus a careful optimization of the nanoparticle 
conjugation can lead to consistent improvements in the overall LFA performance. B) Fixing the dispense 
speed at 50 mm/sec, the use of three different flow rates during the membrane striping produced lines 
with different widths. As expected using a flow rate of 2 µL/cm generated a thicker line than those obtained 
using lower flow rates.  
 
27. Sample pad preparation (Steps 27-28): Pre-treat the sample pad by dipping it into sample pad 
buffer until fully wet.  
28. Dry the sample pad at 37 °C for 2 hours in the oven. 
29. Conjugation pad preparation (Steps 29-39): Set the dispense rate of the test and control line 
pumps to 0 µL/mm. 
30. Set the air pressure at 0.3-0.6 bar. 
31. Fill the spraying pump with MilliQ water and dispense at least 10 syringe volumes to thoroughly 
clean the pump. 
32. Empty the MilliQ water of the tube and syringe. 
33. Take at least 100 µL of the AuNP-antibody conjugation solution from Step 16 and prime it in the 
spraying syringe.  
CRITICAL STEP: the volume of AuNP-antibody conjugation solution depends on dispense distance, 
dispense rate and bed volume of syringe (see Step 35).  
34. Prime the pumps until a drop of the conjugation solution flows out of nozzle and place the 
conjugate pad on the vacuum table. 
CRITICAL STEP: Place the pad on a clean and thin plastic support plate in order to avoid the 
conjugation solution from sticking onto the vacuum table. 
35. Setup the spraying pump with a dispense rate of 5 µL/mm and a speed of 50 mm/sec 
36. Press RUN to dispense the conjugation solution onto the conjugate pad. 
37. Press ‘un-prime’ to recycle the conjugation solution. 
38. Clean the pumps using MilliQ water, followed by 0.1 M HCl, MilliQ water, 0.1 M NaOH and again 
MilliQ water. Un-prime the system and keep the pumps in a liquid-free state. 
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CRITICAL STEP: Dispense at least 10 syringe volumes during each washing step (dispense rate of 5 
μL/cm and a speed of 50 mm/sec). The pumps should be thoroughly cleaned monthly using a 
weak detergent (0.05% Sodium C14-16 olefin sulfonato), 10 % (vol/vol) bleach, HCL (0.01 M pH 2) 
and NaOH (0.01 M, pH 12) 
39. Dry the conjugate pad in the vacuum chamber for at least 60 min. 
CRITICAL STEP: Check that the conjugate pad is fully dry by evaluating the stiffness of the glass 
fibre. Check that the AuNPs solution is homogeneously distributed throughout the conjugate pad 
by evaluating the colour of the test line by naked eye.  
 
40. Assembly of the strips (Steps 40-41): Use the plastic guides of the laminated card in order to 
accordingly assemble the pads (see Figure 7). After the membrane, place the absorbent pad, then 
the conjugate pad and finally the sample pad.  
TROUBLESHOOTING:  
41. Cut the strip at 3 mm width using the strip cutter. 
CRITICAL STEP: In the absence of a dedicated strip cutter, it is possible to cut the strips using a 
manual guillotine, although the strip to strip variability will be higher. 
PAUSE POINT: The tests can be stored in a sealed bag with desiccants at 4 °C for as long as the 






Figure 7 – Step by step fabrication of a LFA for the detection of Human IgG. 
 
Assay operation and qualitative evaluation - 1 hour 
42. Prepare dilutions of the sample containing target analyte. In this example we use Human IgG in 
PBS buffer (0, 0.01, 0.03, 0.1. 0.3, 1, 3, 10, 30, 100, 300, 1000 ng/mL). For detailed 
recommendations on the types of samples that can be analysed, see ‘Types of Sample’ in the main 
text. 
43. Drop-cast 70 μL of the sample solution onto the sample pad.  
CRITICAL STEP: The solution should be added dropwiseon top of the sample pad to avoid 
overflow of the sample on top of the conjugate pad and the membrane. This will guarantee that 
the sample moves along the different pads of the LF strip just by capillarity. In addition 
commercial LF strips relying on this type of procedure are often placed in the housing cassette, 
which limits the possibility of overflow and guarantee the application of the sample always in 
the same part of the sample pad.  
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CRITICAL STEP: Alternatively, the strip can be dipped directly into the sample solution, paying 
attention that just the sample pad is in contact with the sample. This will guarantee that the 
sample moves along the different pads of the LF strip just by capillarity. While the dropwise 
method is more convenient from the user perspective (it is more stable and practical), the 
dipping of the LF strip may be helpful during the development phase (minimizing user 
variations) or when washing/running buffers are required (after adding the sample the user 
would just leave the sample inside a tube containing the desired buffer). In addition LFA relying 
on the dipping method do not require a housing cassette since the LF strip is placed vertically 
inside the sample.  
 
44. Wait 15 min and evaluate the strips qualitatively by eye (Fig. 8). Proceed to the next section once 
the signal in the test and control lines stabilizes.   
  
CRITICAL STEP: The appearance of signal in the test and control lines indicate the presence of the 
target analyte (Human IgG in this example) in the sample, while the appearance of signal in the 
control line only indicates the absence of the target analyte in the sample. The signal intensity in 
the test line correlates with the concentration of the target analyte in the sample. The absence of 
the control and test lines makes the LFA not trustworthy, since it indicates a malfunctioning of 
the strip.  
CRITICAL STEP: Use a clear and constant white light source and avoid shadows while evaluating 
the strips by naked eye. 
TROUBLESHOOTING:  
 
Figure 8 – Qualitative analysis of LFAs for the detection of Human IgG.  The intensity of the test line 




Quantitative evaluation - 30 minutes 
45. Fix the strips in a flat surface under the camera holder (i.e. a tripod or similar). 
46. Fix the camera on the camera holder.  
47. Adjust the camera parameters and take pictures of the strips. 
CRITICAL STEP: To facilitate the comparison between different strips and different days it is 
essential to use always the same set-up, including the distance between the camera and the 
strips, the light source (ideally in a dark room to prevent contamination from ambient light), 
and the camera parameters (ISO, aperture, shutter speed and focus). 
CRITICAL STEP: We cannot provide specific indications on the camera parameters to employ, 
since they may vary from place to place and form camera to camera. Nevertheless, we 
recommend to fix all the set up conditions at the beginning of the development and to keep 
them constant. A simple “trick” to speed up the optimization of the best camera conditions is 
to take the first picture using the “automatic” mode of the camera. Then using such parameters 
as starting point to find the optimal ones.   
48. Open the pictures with Image J software (see Fig. 9 A-B). 
49. Select the green channel by selecting Image – Colour – Split Channel – Green channel (see Fig. 9 
C). 
CRITICAL STEP: The use of the green channel is recommended for the analysis of red labels such 
as gold nanoparticles since it provides the highest sensitivity.  
50. With the “straight” command draw a line along the membrane (see Fig. 9 D) 
CRITICAL STEP: The width of the straight line should be increased till covering most of the strip in 
order to obtain more reproducible results.   
51. Extract the plot profile by selecting Analyze – Plot profile – List (see Fig. 9 E) 
52. Export the results in a data analysis software (Excel, Origin, etc.)  
53. Calculate the peak intensity of the test line and plot it vs the target analyte concentration used 
(Fig. 9F). 
CRITICAL STEP: the peak intensity can be obtained subtracting the peak value of the test line from 
the background value. Overall it is not recommended to use the peak value of the control line as 
reference for the test line one, since high target analyte concentrations (in a sandwich assay) may 
lead to a dramatic depletion in the concentration of AuNPs after the test line, which may produce 
a decrease in the control line intensity (if compared to strips that used low target concentrations).  
54. Fit the data to a four-parameter logistic curve (sigmoidal curve).215 
CRITICAL STEP: In case of using a range of target concentrations that generates both non-
responsive and saturated signals the best data fitting is generally obtained using a four-parameter 
logisitic curve (a sigmoidal curve). Instead if the calibration is done using a range of target 
concentration focused on the dynamic range of the fitted sigmoidal curve (between the 10% and 
90% of the maximum signal) it is possible to approximate the fit to a linear curve. Overall, 
sigmoidal approximation is generally accepted for competitive immunoassays (since they more 
closely represent an ideal Langmuir model than an immune sandwich assay), whereas linear 
approximation of the initial part of concentration dependence is often preferred for immune 
sandwich assays. 
55. Carry out the desired statistical analysis such as calculating the limit of detection (LoD) and the 
limit of quantification (LoQ). 
CRITICAL STEP: It is possible to calculate the limit of detection (LoD = value of the blank + 3 times 
its standard deviation) and limit of quantification (LoQ = value of the blank + 10 times its standard 
deviation), which in this case is 0.77 nM and 4.62 nM respectively. As shown also by this example 
dataset (where the LoD signal is almost undistinguishable from the non-responsive portion of the 
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fitted curve), although LoD is a generally accepted method to evaluate LFAs, it is sometimes not 
statistically robust since it does not count for the variance in the test signals. We  refer the reader 
to the following references describing improved methods to calculate the LoD of LFAs.203,216–218  
 
 
Figure 9 – Quantitative analysis of LFA using ImageJ and fitting the results to a four-parameter logistic 
curve (sigmoidal curve). A) Open the ImageJ software. B) Open the file containing the photo of the strip(s). 
C) For LFAs employing red labels (i.e. AuNPs) the use of the green channel maximizes the sensitivity of the 
analysis. D) The use of the straight command followed by E) the plot profile allows the representation of 
the signal profile along a LFA strip. We recommend to use a line width that covers most of the strip in order 
to have more reliable results. From the plot profile it is possible to extract the values and use data analysis 
software to calculate the peak value of the test line. It is obtained by subtracting the background signal 
from the peak value. F) The data must then be plotted against the target concentration, in this case using 
a four-parameter logisitic curve (a sigmoidal curve). It is then possible to carry out statistical analysis such 




- END OF BOX 1 -  
Table 4: Troubleshooting Table 
STEP Problem Reason Solution 
   The target analyte is not 
commercially available. 
 The target analyte is too 
expensive. 
 The target analyte is new or 
not common. 
 
 Produce your own target 
analyte. 
 Purify the target analyte from 
real samples. 
   Bioreceptors are not 
commercially available. 
 Bioreceptors are too 
expensive. 
 The target analyte is new or 
not common. 
 
 Evaluate different types of 
bioreceptors (see table 3). 
 Develop new bioreceptors. 
 Consider changing assay 
format from sandwich to 
competitive assay.  
   Bioreceptors are not 
sensitive and specific enough, 
as determined using standard 
techniques (ELISA. SPR, etc.). 
 The target analyte is new or 
not common. 
 The target 
analyteconcentration is too 
low. 
 
 Develop new bioreceptors. 
 Consider if sample treatment, 
target pre-concentration or 
signal amplification could 
solve the issue. 
 Re-evaluate your assay’s 
goals. 
   Nanoparticles are not stable 
in solution after conjugation 
with the bioreceptor. 
 The ionic strength of the 
buffer is too high. 
 The conjugation was not 
successful. 
 
 Decrease buffer ionic 
strength or increasing 
amount of surfactants or 
BSA. 
 Increase the amount of 
bioreceptor during the 
conjugation. 
 Block the nanoparticles with 
stabilizing agents (i.e. BSA). 
 Evaluate different 
conjugation strategies.  
   Nanoparticles do not flow 
upon rewetting. 
 Nanoparticles are stuck on 
the conjugate pad.  
 Increase the sugar 
concentration in the 
conjugate pad buffer. 
 Verify the conjugate pad is 
fully dried before adding the 
sample. 
 Increase the amount of 
surfactant in the running 
buffer. 
 If using polyclonal antibodies 
control for the formation of 
immune-aggregates. 
 Change conjugate pad 
material. 
 Re-optimize conjugation. 
   Sample does not reach the 
conjugate pad. 
 The sample pad is clogged. 
 The sample pad and the 
conjugate pad are not in 
contact.  




 Introduce an extra filtration 
or sample treatment to 
remove bigger particles.  
 Use an extra running or 
washing buffer. 
 Assure the sample and 
conjugate pad are overlaid.  
 Assure the sample pad is not 
compressed by the cassette. 
 Change composition of the 
sample pad buffer increasing 
amount of surfactant. 
   Test line does not show up, 
but the control line does. 
 The target concentration is 
too low or too high. 
 The test line bioreceptor was 
not properly striped.  
 If using a sandwich assay the 
bioreceptors bind the same 
epitope. 
 Check a wider range of target 
concentrations (sandwich 
assay can present also the 
hook effect169). 
 Decrease ionic strength of 
striping buffer. 
 Remove/decrease 
surfactants from striping and 
running buffers.  
 Increase concentration of 
bioreceptor or add other 
molecules (BSA) to stabilize 
it.  
 Remove membrane blocking 
(if any), or decrease blocking 
agent concentration. 
 Increase amount of label in 
conjugate pad.  
 Assure the bioreceptor is 
completely dried before 
using the LFA. 
 Change bioreceptor.  
   Control line does not show 
up, but the test line does.  
 The control line bioreceptor 
was not properly striped. 
 The bioreceptor-nanoparticle 
conjugate concentration is 
too low.  
 Add a different nanoparticle 
specific for the control line. 
 Decrease ionic strength of 
striping buffer. 
 Remove surfactants from 
striping buffer.  
 Increase amount of 
nanoparticles in conjugate 
pad.  
 Change to a different capture 
bioreceptor. 
   Both control and test lines do 
not show up. 
 The bioreceptor-nanoparticle 
conjugation was not 
successful.  
 The striping was wrong. 
 Target concentration is too 
high. 
 Change conjugation strategy. 
 Change striping buffer, 




 Decrease surfactant 
concentration in the running 
buffer.  
 Use a new membrane (in 
case it is expired) or change 
material.  
 Verify the capture 
bioreceptors are actually 
striped on the membrane.  
 Verify the labelled-
bioreceptor is not expired.  
 Dilute the sample.  
   The sensor is not specific.  Nonspecific interactions 
induce the accumulation of 
label on the test line even in 
the absence of target.  
 Change to different 
bioreceptors.  
 Block the membrane. 
 Increase blocking agents in 
sample pad and running 
buffers. 
 Increase amount of 
surfactants in the striping, 
sample pad and running 
buffers. 
 Increase ionic strength in the 
sample pad and running 
buffers. 
 Change pH in the sample pad 
and running buffers. 
 Use a faster flow membrane.  
 Actively remove possible 
contaminants. 
   The cut-off value is not 
adequate for the application 
(i.e. the sensor is too much or 
not enough sensitive to 
detect the target 
concentration of interest).  
 The sensor cannot detect 
application-relevant 
concentrations of target. 
 Increase amount of 
nanoparticles. 
 Use a slower flow 
membrane. 
 Change amount of 
bioreceptors on the test line.  
 Change ionic strength, pH 
and surfactants 
concentration in the buffers. 
 Change type of nanoparticles 
and sensing strategy.  
 Pre-concentrate or dilute the 
sample depending on what is 
appropriate.  
 Include a signal amplification 
step. 
 Change to different 
bioreceptors.  
   The sensitivity is not 
adequate for the application 
 The sensor cannot accurately 
differentiate two close 
concentration values 




 Use a slower flow 
membrane. 
 Change amount of 
bioreceptors on the test line.  
 Change ionic strength, pH 
and surfactants 
concentration in the buffers. 
 Change type of nanoparticles 
and sensing strategy. 
 Pre-concentrate the sample.  
 Apply a signal amplification 
strategy. 
 Change to different 
bioreceptors. 
 Modify strip dimensions, 
architecture. 
 Consider the pre-treatment 
of the sample (purification, 
amplification, not dilution, 
etc.) and/or increase the 
sample volume. 
 Improve quantification 
device (camera, sensor, 
software, etc.). 
   The sensor does not show 
repeatability  
 Using the same target 
concentration, the sensor 
produces different signals.  
 Verify the fabrication steps 
and the ambient conditions 
are constant from batch to 
batch. 
 Use a constant light source. 
 If using a reader, use the 
same parameters (i.e. 
exposure, focus, etc.). 
 Assure the proper storage of 
the LFA.  
   The sensor is not 
reproducible 
 Other developers or users do 
not obtain the same 
response.230  
 Verify the fabrication steps 
and the ambient conditions 
are constant from batch to 
batch. 
 Use a constant light source. 
 Define protocols to store all 
the reagents involved and 
control parameters such as 
pH during all the steps. 
 Evaluate incubation steps at 
different 
times/temperatures. 
 Define expiration dates for 
reagents, materials and the 
device itself. 
 Provide a more precise and 
easier to understand protocol 
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to facilitate the sensor 
operation by the user. 
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Supplementary Table 1 – Costs associated with a single LF strip 
 
Material/Reagent Cost in USD 
Laminated card 0.0080 
Nitrocellulose membrane 0.0204 
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Conjugate pad 0.0044 
Sample and Absorbent pad  0.0046 
Antibodies for test and control lines 0.0450 
Gold nanoparticles  0.1700 
Conjugate pad buffer 0.0031 
Antibodies for conjugate 0.1416 
Sample pad buffer 0.0047 
Total 0.4018 
This estimation is based on the product prices provided by suppliers in 2019 and considering a 6 mm wide 
strip. To the final cost of a single LFA of 0.4018 $ must be added the cost for the dispenser (which can be 
around 20,000.00 $, but can be even lower for lab scale applications) and the salary of personnel/facility 
(not estimable since it may vary significantly between countries).  
 
